Switch theme
Sign up to access all valuation multiples
Medacta Group SA is involved in developing, manufacturing and distributing orthopedic and neurosurgical medical devices. The company offers solutions for Hip, Knee, Shoulder and Spine. The majority of the company's revenue is generated from Europe, Middle East, and Africa (EMEA) and the rest from other regions.
1999
1.9K+
LTM Revenue $662M
LTM EBITDA $180M
$3.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Medacta Group has a last 12-month revenue (LTM) of $662M and a last 12-month EBITDA of $180M.
In the most recent fiscal year, Medacta Group achieved revenue of $709M and an EBITDA of $193M.
Medacta Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Medacta Group valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $662M | XXX | $709M | XXX | XXX | XXX |
| Gross Profit | $448M | XXX | $480M | XXX | XXX | XXX |
| Gross Margin | 68% | XXX | 68% | XXX | XXX | XXX |
| EBITDA | $180M | XXX | $193M | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 27% | XXX | XXX | XXX |
| EBIT | $106M | XXX | $109M | XXX | XXX | XXX |
| EBIT Margin | 16% | XXX | 15% | XXX | XXX | XXX |
| Net Profit | $82.9M | XXX | $87.5M | XXX | XXX | XXX |
| Net Margin | 13% | XXX | 12% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $192M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Medacta Group's stock price is CHF 135 (or $162).
Medacta Group has current market cap of CHF 2.7B (or $3.2B), and EV of CHF 2.9B (or $3.5B).
See Medacta Group trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.5B | $3.2B | XXX | XXX | XXX | XXX | $4.56 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Medacta Group has market cap of $3.2B and EV of $3.5B.
Medacta Group's trades at 4.9x EV/Revenue multiple, and 18.0x EV/EBITDA.
Equity research analysts estimate Medacta Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Medacta Group has a P/E ratio of 36.4x.
See valuation multiples for Medacta Group and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.2B | XXX | $3.2B | XXX | XXX | XXX |
| EV (current) | $3.5B | XXX | $3.5B | XXX | XXX | XXX |
| EV/Revenue | 4.9x | XXX | 4.9x | XXX | XXX | XXX |
| EV/EBITDA | 18.0x | XXX | 18.0x | XXX | XXX | XXX |
| EV/EBIT | 30.6x | XXX | 31.8x | XXX | XXX | XXX |
| EV/Gross Profit | 7.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | 36.4x | XXX | 36.9x | XXX | XXX | XXX |
| EV/FCF | 119.8x | XXX | 1176.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMedacta Group's last 12 month revenue growth is 12%
Medacta Group's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
Medacta Group's rule of 40 is 36% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Medacta Group's rule of X is 58% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Medacta Group and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 27% | XXX | XXX | XXX |
| EBITDA Growth | 13% | XXX | 18% | XXX | XXX | XXX |
| Rule of 40 | 36% | XXX | 39% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 58% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 36% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 4% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 52% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Medacta Group acquired XXX companies to date.
Last acquisition by Medacta Group was XXXXXXXX, XXXXX XXXXX XXXXXX . Medacta Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Medacta Group founded? | Medacta Group was founded in 1999. |
| Where is Medacta Group headquartered? | Medacta Group is headquartered in Switzerland. |
| How many employees does Medacta Group have? | As of today, Medacta Group has 1.9K+ employees. |
| Is Medacta Group publicy listed? | Yes, Medacta Group is a public company listed on SWX. |
| What is the stock symbol of Medacta Group? | Medacta Group trades under MOVE ticker. |
| When did Medacta Group go public? | Medacta Group went public in 2019. |
| Who are competitors of Medacta Group? | Similar companies to Medacta Group include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Medacta Group? | Medacta Group's current market cap is $3.2B |
| What is the current revenue of Medacta Group? | Medacta Group's last 12 months revenue is $662M. |
| What is the current revenue growth of Medacta Group? | Medacta Group revenue growth (NTM/LTM) is 12%. |
| What is the current EV/Revenue multiple of Medacta Group? | Current revenue multiple of Medacta Group is 4.9x. |
| Is Medacta Group profitable? | Yes, Medacta Group is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Medacta Group? | Medacta Group's last 12 months EBITDA is $180M. |
| What is Medacta Group's EBITDA margin? | Medacta Group's last 12 months EBITDA margin is 27%. |
| What is the current EV/EBITDA multiple of Medacta Group? | Current EBITDA multiple of Medacta Group is 18.0x. |
| What is the current FCF of Medacta Group? | Medacta Group's last 12 months FCF is $27.1M. |
| What is Medacta Group's FCF margin? | Medacta Group's last 12 months FCF margin is 4%. |
| What is the current EV/FCF multiple of Medacta Group? | Current FCF multiple of Medacta Group is 119.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
